Clinical Trials on Granuloma, Plasma Cell

Total 32633 results

Roswell Park Cancer Institute
GlaxoSmithKline

Recruiting

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

Plasma Cell Myeloma

United States
Emory University

Completed

Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy

Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); National...

Completed

Chaplain-Delivered Compassion Meditation to Improve Quality of Life in Patients Receiving a Stem Cell Transplant

Lymphoma | Plasma Cell Myeloma

United States
Alexion Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis

AL Amyloidosis

United States, Germany, Spain, United Kingdom, France, Korea, Republic of, Poland, Netherlands, Japan, Belgium, Greece, Australia, Austria, Brazil, Canada, China, Czechia, Israel, Italy, Russian Federation
Thomas Jefferson University

Completed

Exercise Prescription for the Improvement of Quality of Life in Elderly Patients With Multiple Myeloma

Plasma Cell Myeloma

United States
National Cancer Institute (NCI)
Georgetown University; Hackensack Meridian Health

Terminated

Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma

Myeloma-Multiple | Myeloma, Plasma-Cell | Myelomatosis

United States
National Cancer Institute (NCI)

Completed

Collection of Transplant Stem Cells for Plasma Cell Myeloma

Multiple Myeloma | Plasma Cell Myeloma

United States
University of Utah

Terminated

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

Primary Myelofibrosis | Anemia | Thrombocytopenia | Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | IDH2 Gene Mutation | IDH1 Gene Mutation | Secondary Myelofibrosis | ASXL1 Gene Mutation | EZH2 Gene Mutation

United States
University of California, Davis

Completed

Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
The Cleveland Clinic
National Cancer Institute (NCI)

Terminated

T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Precancerous/Nonmalignant Condition | Secondary Myelofibrosis | Multiple Myeloma and Malignant Plasma Cell Neoplasms

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Terminated

Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
University of California, San Francisco
National Cancer Institute (NCI)

Completed

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Advanced Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant

Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
LaNova Medicines Limited

Withdrawn

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Relapsed or Refractory Multiple Myeloma | Other Plasma Cell Diseases
Srinivas Devarakonda

Terminated

Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Withdrawn

Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
Ohio State University Comprehensive Cancer Center
Celgene

Completed

HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
University of Athens
Pierre and Marie Curie University

Recruiting

Validation of the 4TS RAM in the Prevention of Venous Thromboembolism in Patients With Plasma Cell Dyscrasias. (ROADMAP-MM)

Multiple Myeloma | Venous Thromboembolism

Greece
New York University

Recruiting

Comparison Between RCT in Single and Two Visits, With and Without Intracanal Dressing, in Apical Repair

Tooth, Nonvital | Teeth, Endodontically-Treated | Periapical Granuloma | Periapical Periodontitis, Chronic Nonsuppurative

Brazil
University of Michigan

Terminated

UVA1 Light for Scleroderma and Similar Conditions

Scars | Keloid | Scleroderma | Granuloma Annulare | Acne Keloidalis Nuchae

United States
University of Maryland, Baltimore
University of Maryland Greenebaum Cancer Center

Completed

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Anemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
Aronex Pharmaceuticals

Completed

Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Infection | Multiple Myeloma and Plasma Cell Neoplasm

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Terminated

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins

Red-Cell Aplasia, Pure
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa

Pure Red-cell Aplasia

United Kingdom, Sweden, South Africa, Brazil, Norway, France, Thailand
Mayo Clinic
National Cancer Institute (NCI)

Completed

Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
Emory University
Bristol-Myers Squibb; National Cancer Institute (NCI); City of Hope Medical Center and other collaborators

Completed

Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
The Cleveland Clinic
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma

Multiple Myeloma | Anemia | Plasma Cell Neoplasm

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy

Multiple Myeloma | Thromboembolism | Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Completed

Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Light Chain Deposition Disease

United States
Roswell Park Cancer Institute

Completed

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
Northside Hospital, Inc.

Terminated

Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
Multiple Myeloma Research Foundation

Completed

Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma | t(11;14)

United States
University of Washington
Bristol-Myers Squibb

Active, not recruiting

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma and other conditions

United States
Pernille Pedersen
Copenhagen University Hospital, Hvidovre

Completed

Treatment of Granuloma Umbilical in Newborn Babies

Fetus or Newborn Affected by Condition of Umbilical Cord

Denmark
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Recurrent T-Cell... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma Survivors

Plasma Cell Myeloma

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

Non-Hodgkin's Lymphoma | Plasma Cell Myeloma

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

Lymphoproliferative Disorders | Leukemia | Multiple Myeloma | Myelodysplastic Disorders | Plasma Cell Dyscrasia

United States
Peking Union Medical College Hospital

Unknown

Circulating Plasmablast in Diagnosis and Relapse Prediction of IgG4-RD

Plasmablast/Plasma Cells in Diagnosis of IgG4-RD | Plasmablast/Plasma Cells in Relapse Prediction of IgG4-RD

China
Columbia University
National Cancer Institute (NCI)

Terminated

Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms | Childhood Langerhans Cell Histiocytosis | Adult Langerhans Cell Histiocytosis

United States
Johnson & Johnson Pharmaceutical Research & Development...
Janssen-Cilag International NV

Completed

Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney Failure (PRIMS)

Chronic Kidney Failure | Pure Red-Cell Aplasia

Poland, United Kingdom, Belgium, Germany, Spain, Portugal, Australia, Switzerland, Finland, Greece, Sweden, Netherlands, Norway, Ireland, Denmark
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Terminated

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Multiple Myeloma and Plasma Cell Neoplasm | Drug/Agent Toxicity by Tissue/Organ

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Neoplasms | Multiple Myeloma and Malignant Plasma Cell Neoplasms

United States

Clinical Trials on Granuloma, Plasma Cell

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations